Core Insights - Abbott Laboratories' Established Pharmaceuticals Division (EPD) is focused on emerging markets, holding leading positions in significant pharmaceutical markets such as India and China, which positions the company for sustained growth in branded generics [1][3] - Despite a projected deceleration in growth for emerging markets to approximately 3.7% by 2025, Abbott's EPD sales increased by 6.9% in Q2 2025, with over half of its top markets achieving double-digit growth [2][3] - Abbott's strategic focus on biosimilars and a five-year compound annual growth rate (CAGR) of 8% for EPD indicates strong growth potential [3] Financial Performance - Year-to-date, Abbott shares have increased by approximately 16.8%, outperforming the Medical Product industry and the S&P 500, which rose by 3.5% and 7.7% respectively [4] - In Q2 2025, Abbott's Diabetes Care sales grew by 19.6% organically, driven by the success of the FreeStyle Libre CGM system [9][10] - Abbott expects full-year 2025 organic sales growth to be in the range of 7.5-8.0%, with adjusted diluted earnings per share projected between $5.10-$5.20 [11] Market Dynamics - Abbott's Diagnostics business accounted for 19.5% of total revenues in Q2 2025, with strong demand for routine diagnostic tests contributing to growth [7] - The company is investing $0.5 billion in facilities in Illinois and Texas to expand its presence in the molecular testing market [7] - Abbott's Diabetes Care segment is expanding access to over 6 million users globally through its FDA-cleared over-the-counter CGMs [8] Challenges and Outlook - Abbott faces challenges from trade tensions and geopolitical issues, which are impacting demand for MedTech products and increasing costs [12][14] - The Chinese government's volume-based procurement policies are expected to negatively affect Abbott's Diagnostics and EPD businesses, with a projected $700 million headwind to full-year 2025 sales [14] - Despite these challenges, Abbott's operational performance remains strong, with expectations for consistent earnings and margin performance in 2025 [19] Valuation - Abbott's forward five-year price-to-sales (P/S) ratio is 4.92X, which is lower than the industry average of 5.38X, indicating a potentially attractive investment opportunity [15][20]

Core Insights - Abbott Laboratories' Diabetes Care business is experiencing significant growth, primarily driven by the FreeStyle Libre continuous glucose monitoring (CGM) platform, which has achieved global leadership in the CGM market for both Type 1 and Type 2 diabetes users [1][2]. Company Developments - Abbott has received FDA approvals for two new over-the-counter CGM systems, Lingo and Libre Rio, expanding its consumer reach and marking a new era in the U.S. market [2][8]. - In Q2 2025, Abbott's CGM sales exceeded $1.90 billion, reflecting a 19.6% organic growth, with U.S. Libre sales increasing nearly 26% [4][8]. - The upcoming launch of Abbott's dual-analyte sensor, which includes ketone monitoring, is expected to enhance its market share, particularly among intensive insulin users [4][8]. Market Trends - The diabetes care devices market is projected to grow significantly, reaching $99.81 billion by 2035, with a compound annual growth rate (CAGR) of 9.6% from 2025 to 2035 [3]. - The increasing aging population, rising obesity rates, and sedentary lifestyles are driving demand in this fast-growing market [3]. Competitive Landscape - Competitors like DexCom and Tandem Diabetes are also expanding their offerings in the CGM space, with DexCom focusing on its G6 and G7 systems and Tandem enhancing its pump portfolio and digital solutions [5][6]. Financial Performance - Year-to-date, Abbott's shares have increased by 19.7%, outperforming the industry growth of 7.9% and the S&P 500's growth of 21.5% [7]. - Abbott currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 4.84X, below the industry average of 5.63X [10].

达能首席财务官Juergen Esser在业绩会上表示，"中国市场对专业特殊营养产品的需求持续强劲，增长主要由爱他美奇迹Essensis系列拉 动，市场份额持续提升"。 同样表现亮眼的，还有菲仕兰专业营养品业务集团，其营收增长18.1%至7.18亿欧元，营业利润增长61%至2.19亿欧元，皇家美素佳儿 市场份额持续增长。 截至7月31日，雀巢、达能、菲仕兰、雅培等外资乳企的上半年"成绩单"悉数出炉，在中国市场的业绩整体向好。其中达能旗下主力品 牌爱他美、菲仕兰旗下皇家美素佳儿等高端产品增长迅猛，成为增长的主要原因。业内分析人士指出，中外奶粉企业已经步入"百花齐 放"的局面，未来能否持续增长在于高端产品的较量。 业绩向好 从财报来看，四家外资乳企上半年业绩整体向好。 达能、菲仕兰、雅培均实现中个位数营收增长。7月30日，达能发布的2025年半年报显示，销售额同比增长4.2%至137.37亿欧元，其中 销量/组合上升2.6%，定价上涨1.7%；7月23日，菲仕兰发布的2025年半年报显示，营收增长6.4%至68.47亿欧元；7月18日，雅培公布 的2025年第二季度财报显示，实现营收约为111.42亿美元，同比增 ...

来源：ESG评级中心 据新浪财经ESG评级中心，2025年07月30日，雅培（ABT.US）MSCI（明晟）ESG评级由BB调升至 BBB。 点击查看更多企业ESG评级。 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-2189 ABBOTT LABORATORIES An Illinois Corporation I.R.S. Employer Identification No. 36-0698440 100 Abbott Park Road ...

Core Insights - The article highlights the significant increase in CEO compensation within the global medical technology sector, with the top ten MedTech CEOs earning nearly $680 million in total, reflecting an average year-on-year increase of 46% [1]. Group 1: CEO Compensation Overview - DaVita's CEO, Javier Rodriguez, saw his total income rise to $164.07 million, a staggering increase of 317.29%, primarily due to the cashing out of a high-value stock option granted in 2019 [4]. - Thermo Fisher Scientific's CEO, Marc Casper, earned a total of $116.32 million, up 43.85%, following a strategic acquisition of Olink for $3.1 billion [7]. - Stryker's CEO, Kevin Lobo, reported a total income of $78.94 million, a 32.46% increase, driven by significant acquisitions and internal growth strategies [10]. - Boston Scientific's CEO, Michael Mahoney, achieved a total income of $63.31 million, marking a 64.88% increase, largely due to the success of the Farapulse system and multiple acquisitions [13]. - Intuitive's former CEO, Gary Guthart, earned $54.99 million, a 31.50% increase, as he oversaw major upgrades to the da Vinci platform [16]. - Solventum's CEO, Bryan Hanson, reported a total income of $44.40 million, an 85.80% increase, following the company's successful IPO and strategic divestitures [19]. - Abbott's CEO, Robert Ford, earned $41.15 million, a 36.30% increase, as the company returned to growth post-COVID [22]. - Johnson & Johnson MedTech's CEO, Joaquin Duato, experienced a decline in total income to $40.12 million, down 18.63%, despite the company's revenue growth [25]. - Masimo's former CEO, Joe Kiani, earned $38.11 million, a 54.73% increase, despite being ousted from the company [28]. - Danaher's CEO, Rainer Blair, reported a total income of $38.10 million, a 17.16% increase, as the company shifted focus from acquisitions to internal innovation [30]. Group 2: Trends in Executive Compensation - The article notes that stock option cash-outs significantly influenced the income spikes for CEOs at companies like DaVita and Intuitive, with some executives earning over $100 million in a single year [31]. - There is a trend towards increasing performance-based incentives, as seen in companies like Thermo Fisher and Abbott, which are moving away from time-based RSUs to align more closely with shareholder interests [31]. - Organizational changes and leadership transitions at companies like Sonova and Masimo are closely linked to executive compensation, indicating a strategic alignment between pay and company direction [31].

Core Insights - The author has a strong educational background with a master's degree in Analytics and a bachelor's degree in Accounting, indicating a solid foundation for investment analysis [1] - The author has over 10 years of experience in the investment arena, starting as an analyst and progressing to a management role, showcasing a deep understanding of the industry [1] - The author expresses a personal interest in dividend investing, suggesting a focus on income-generating investments [1] Company and Industry Summary - The author holds long positions in several companies including CTAS, JNJ, WST, O, HRL, LOW, PEP, and ROP, indicating a diversified investment strategy [2] - The article reflects the author's personal opinions and does not involve compensation from the companies mentioned, suggesting an independent analysis [2] - The disclosure emphasizes that past performance is not indicative of future results, highlighting the inherent uncertainties in investment decisions [3]

Group 1: Event Overview - The ninth China International Import Expo (CIIE) has officially launched its exhibition recruitment, with over 40 companies signing contracts, covering an exhibition area of 30,000 square meters [1] - The eighth CIIE has signed contracts for over 330,000 square meters of exhibition space, with 170 companies and 27 institutions recognized as "full attendance" participants [2] - The event will feature participation from 60 overseas exhibition groups from 40 countries and regions, with record-high participation from countries like Canada, Malaysia, New Zealand, Norway, and Peru, reflecting confidence in the Chinese economy [2] Group 2: Exhibitor Highlights - L'Oréal, a long-time exhibitor, will showcase new brands and technologies, marking the largest debut scale in its history, and will celebrate the 20th anniversary of its R&D center in China [6] - New Zealand's Fonterra will globally launch three new product categories, including "A2 Grass-fed Pure Milk," targeting the health-conscious Chinese consumer market [9][10] - Medtronic will present over 100 innovative medical technology products, including six global debuts, emphasizing the transformation of exhibition items into market products [20][24] Group 3: Innovation and New Products - The eighth CIIE will introduce a special area for products from least developed countries and a "cross-border e-commerce selection platform" [2] - Siemens Healthineers will showcase its largest exhibition area to date, featuring groundbreaking medical technologies such as the world's first life-sensing PET/MR system [20] - Abbott will debut its breakthrough cardiovascular technology, the Diamondback 360™ system, which aims to improve treatment reliability for coronary artery blockages [21]

"在雅培，我们一直致力于以长期可持续的发展方式，让健康解决方案覆盖更广泛的地区。我们持续多 年参展进博会，便彰显了致力于将前沿医疗科技带给全球更多人的承诺。"雅培核心诊断业务中国副总 裁谭敏杰表示，"我们众多的创新成果通过进博会平台走向大众，并推动医疗健康行业的高质量发展和 健康获益。" 特别值得关注的是，心血管领域突破性科技雅培Diamondback 360™冠状动脉轨道旋磨介入治疗系统将 在进博首秀，该系统通过在冠状动脉内使用可旋转的钻石涂层旋磨头在血管内的高速旋磨，消除血管内 阻塞管腔的钙化斑块，为后续的支架置入治疗"磨"出更稳妥的通路，达到更为可靠的治疗效果。 7月25日，上海——在第八届中国国际进口博览会（以下简称"进博会"）倒计时100天之际，全球领先的 医疗健康公司雅培宣布将再次参展进博会。今年，雅培将继续亮相医疗器械及医药保健展区，呈现基于 大众健康管理需求洞察所取得的最新创新成果。这些成果覆盖医疗健康的多个领域，其中包括为疾病提 供突破性诊疗方案的医疗器械，精准检测赋能医疗决策的诊断系统，帮助人们恢复及保持健康的药品， 以及提供全面科学营养支持的营养品。 连续六年参展进博会，雅培已经展示了数 ...

Core Viewpoint - Investors in the Medical - Products sector should consider Envista (NVST) and Abbott (ABT) for potential value opportunities, with NVST currently presenting a more attractive option based on various valuation metrics and earnings outlook [1][3][7]. Valuation Metrics - NVST has a forward P/E ratio of 18.81, while ABT has a higher forward P/E of 24.16, indicating that NVST may be undervalued compared to ABT [5]. - The PEG ratio for NVST is 1.23, suggesting a better valuation relative to its expected earnings growth compared to ABT's PEG ratio of 2.36 [5]. - NVST's P/B ratio stands at 1.09, significantly lower than ABT's P/B ratio of 4.41, further indicating NVST's relative undervaluation [6]. Earnings Estimate Revisions - NVST has experienced stronger estimate revision activity, which is a positive indicator for its earnings outlook compared to ABT [3][7]. - The Zacks Rank system rates NVST as 2 (Buy) and ABT as 3 (Hold), reflecting a more favorable earnings estimate revision trend for NVST [3]. Value Grades - NVST has been assigned a Value grade of B, while ABT has a Value grade of C, highlighting NVST's superior valuation metrics [6].